[
  {
    "ts": null,
    "headline": "AbbVie to buy Capstan for up to $2.1 billion in immunology push",
    "summary": "(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases.  The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira, lost patent protection.  Capstan develops CAR-T therapies, which use a patient's own immune cells, specifically T-cells, to fight diseases.",
    "url": "https://finnhub.io/api/news?id=1ae7614f475c00531f3dbe2acbf715de5078e4f06d6d3394596db612a35b334f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751287323,
      "headline": "AbbVie to buy Capstan for up to $2.1 billion in immunology push",
      "id": 135666209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases.  The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira, lost patent protection.  Capstan develops CAR-T therapies, which use a patient's own immune cells, specifically T-cells, to fight diseases.",
      "url": "https://finnhub.io/api/news?id=1ae7614f475c00531f3dbe2acbf715de5078e4f06d6d3394596db612a35b334f"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?",
    "summary": "VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.",
    "url": "https://finnhub.io/api/news?id=eee75656e22e9516b0e2eb08630014ff6c43cf937de27626bd9fb7712c573b0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751286600,
      "headline": "Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?",
      "id": 135671797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.",
      "url": "https://finnhub.io/api/news?id=eee75656e22e9516b0e2eb08630014ff6c43cf937de27626bd9fb7712c573b0d"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated(NasdaqGS: VRTX) added to Russell 1000 Dynamic Index",
    "summary": "Vertex Pharmaceuticals Incorporated added to Russell 1000 Dynamic Index...",
    "url": "https://finnhub.io/api/news?id=d2f0ab2e6a928ca14c785bd3e09ebde63469b652cc592268da0ee5d6e5d62e56",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751280780,
      "headline": "Vertex Pharmaceuticals Incorporated(NasdaqGS: VRTX) added to Russell 1000 Dynamic Index",
      "id": 135653618,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals Incorporated added to Russell 1000 Dynamic Index...",
      "url": "https://finnhub.io/api/news?id=d2f0ab2e6a928ca14c785bd3e09ebde63469b652cc592268da0ee5d6e5d62e56"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated(NasdaqGS: VRTX) dropped from Russell 1000 Value-Defensive Index",
    "summary": "Vertex Pharmaceuticals Incorporated dropped from Russell 1000 Value-Defensive Index...",
    "url": "https://finnhub.io/api/news?id=fc3d8672fe86adfc80414f04bf91a4406914c169ffb9dcdbd3d4cae97035e5a1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751251562,
      "headline": "Vertex Pharmaceuticals Incorporated(NasdaqGS: VRTX) dropped from Russell 1000 Value-Defensive Index",
      "id": 135640495,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals Incorporated dropped from Russell 1000 Value-Defensive Index...",
      "url": "https://finnhub.io/api/news?id=fc3d8672fe86adfc80414f04bf91a4406914c169ffb9dcdbd3d4cae97035e5a1"
    }
  }
]